Alobresib + Enzalutamide
Phase 1/2Terminated 1 views this week 0 watching💤 Quiet
Interest: 24/100
24
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Metastatic Castrate-Resistant Prostate Cancer
Conditions
Metastatic Castrate-Resistant Prostate Cancer
Trial Timeline
Dec 8, 2015 → Sep 3, 2019
NCT ID
NCT02607228About Alobresib + Enzalutamide
Alobresib + Enzalutamide is a phase 1/2 stage product being developed by Gilead Sciences for Metastatic Castrate-Resistant Prostate Cancer. The current trial status is terminated. This product is registered under clinical trial identifier NCT02607228. Target conditions include Metastatic Castrate-Resistant Prostate Cancer.
What happened to similar drugs?
20 of 20 similar drugs in Metastatic Castrate-Resistant Prostate Cancer were approved
Approved (20) Terminated (8) Active (0)
Hype Score Breakdown
Clinical
9
Activity
0
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02607228 | Phase 1/2 | Terminated |
Competing Products
20 competing products in Metastatic Castrate-Resistant Prostate Cancer